{"product_id":"amlx-bcg-matrix","title":"(AMLX) Amylyx Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Amylyx Pharmaceuticals, Inc. BCG Matrix is a company-specific strategy tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAt the end of 2025, Amylyx Pharmaceuticals, Inc. had 0 FDA-approved commercial products, so its Stars bucket was empty. With no approved drug driving sales, it had no asset leading a growing market with durable share. That left Amylyx without the revenue base usually needed to support a Star position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo market-share leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals had no market-share leader in 2026: Relyvrio was withdrawn in April 2024 after its Phase 3 failure, so there was no U.S. sales base to defend. 2025 revenue fell to near zero from Relyvrio, and no other asset had reached commercial leadership. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage only\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc. was still a clinical-stage story, with value tied to pipeline data, not durable sales. The company kept spending on R\u0026amp;D, while commercialization stayed limited after AMX0035 was pulled from the market in 2024. That means the assets could still scale fast, but they were not yet true \"stars\" in BCG terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo recurring product revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAt end-2025, Amylyx Pharmaceuticals, Inc. had no marketed therapy generating recurring product revenue, and product sales were $0 after the AMX0035\/Azur withdrawal. Without revenue growth, it could not fit the Star bucket; value depended on pipeline readouts, not a stable franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo marketed product sales in 2025\u003c\/li\u003e\n\u003cli\u003eProduct revenue = $0\u003c\/li\u003e\n\u003cli\u003ePipeline drove valuation\u003c\/li\u003e\n\u003cli\u003eNo Star without growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eR\u0026amp;D-led portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc.’s portfolio was centered on neurodegeneration research programs, so it fits a pipeline posture, not a high-share commercial one. In BCG terms, that means no Star was present: the value sat in research bets, not in a scaled, dominant market position.\u003c\/p\u003e\n\u003cp\u003eThat profile is typical of a company spending for future upside, with commercial traction still too thin to support a Star label. The key signal is simple: innovation was the asset, not market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo Star business was present\u003c\/li\u003e\n\u003cli\u003eNeurodegeneration pipeline drove value\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D posture, not scale posture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmylyx Stays a Pipeline Story, Not a Revenue Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAt end-2025, Amylyx Pharmaceuticals, Inc. had no FDA-approved product and no recurring product sales, so the Stars bucket stayed empty. 2025 product revenue was $0, and value still came from pipeline readouts, not a dominant commercial asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-approved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStar status\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAmylyx’s BCG matrix maps its pipeline and approved drugs by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of Amylyx Pharmaceuticals, Inc. to spot each business unit’s quadrant and pain points at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists credible sources for Amylyx Pharmaceuticals, Inc. to validate claims fast and support confident, traceable decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 mature franchises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy the end of 2025, Amylyx Pharmaceuticals, Inc. had 0 mature franchises in the Cash Cows quadrant. Cash cows need a long-lived, low-growth product with strong share, and the ALS franchise was withdrawn, leaving no legacy brand to harvest. The quadrant was empty, with no durable cash generator to support the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo steady product cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter Amylyx Pharmaceuticals, Inc. withdrew Relyvrio in April 2024, it had no marketed drug generating repeat sales in FY2025. That means there was no cash-cow product to fund the pipeline, sales force, or trials. The business instead depended on financing and development capital to keep operating.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo royalty stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmylyx reported no royalty income in 2025, so it was not leaning on a large external royalty book. Its cash generation was tied to product sales, not a mature in-market franchise with steady, low-risk harvest cash. So this BCG cell fits: there was no milking asset to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo dividend funding asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc. had no cash cow in late 2025: no marketed product was funding overhead, debt service, or dividends. The company was still in investment mode, with cash being used for R\u0026amp;D and pipeline buildout instead of payouts. That makes this BCG bucket a clear fit: low cash harvest, high reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo dividend-funded asset in late 2025\u003c\/li\u003e\n\u003cli\u003eNo product financing overhead or debt service\u003c\/li\u003e\n\u003cli\u003eCash stayed tied to R\u0026amp;D spending\u003c\/li\u003e\n\u003cli\u003eCompany remained in investment mode\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDevelopment cash used for R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc. had no true cash cow here: available cash was being pushed into R\u0026amp;D and pipeline work, not milking a mature, low-growth asset for profit. In BCG terms, that means the portfolio was still in investment mode, with no self-funding, high-share cash engine to support the rest. That is why development cash use points to \"question mark\" behavior, not \"cash cow\" behavior.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash funded pipeline advancement\u003c\/li\u003e\n\u003cli\u003eNo mature profit center\u003c\/li\u003e\n\u003cli\u003eNot self-funding\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D drained, not generated, cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmylyx Had No Cash Cow in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy FY2025, Amylyx Pharmaceuticals, Inc. had no Cash Cow: Relyvrio was withdrawn in April 2024, no marketed drug generated repeat sales, and royalty income was zero. Cash was still going to R\u0026amp;D and pipeline work, so the business was not harvesting a mature, low-growth asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003ctd\u003eCash cows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003ctd\u003eRoyalty income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eMarketed drug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmylyx Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Amylyx Pharmaceuticals, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. It includes the full, professionally formatted analysis with no hidden changes. What you see here is what you download. Ready for immediate use in research, planning, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelyvrio\/ALBRIOZA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRelyvrio\/ALBRIOZA was Amylyx Pharmaceuticals, Inc. only marketed product, but it was pulled after the PHOENIX ALS trial missed its primary endpoint in September 2024. Sales went to zero after the withdrawal, so in BCG terms it fits a classic dog: low share, low growth, and no remaining cash engine. That collapse also removed Amylyx Pharmaceuticals, Inc. core revenue base, which had been almost entirely tied to one asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePHOENIX ALS failure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePHOENIX, a phase 3 ALS study, did not confirm benefit for Amylyx Pharmaceuticals, Inc.'s AMX0035, so the drug lost its core growth driver. ReLYVRIO generated $381.7 million in 2023 sales, but the PHOENIX miss led to its U.S. and Canada withdrawal in 2024, erasing the commercial case. In BCG terms, this moved the ALS asset into a Dogs profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALS sales wind-down\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ALS sales wind-down is a Dog in Amylyx Pharmaceuticals, Inc. BCG Matrix terms. After the 2024 global withdrawal of AMX0035, the branded ALS sales engine was shut down, and by end-2025 there was no active ALS commercialization platform left to drive growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCanada exit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALBRIOZA was Amylyx Pharmaceuticals, Inc.'s Canadian brand, and the Canada exit wiped out its mature market position there. In BCG terms, that makes it a dead-end commercial asset: no growth runway, shrinking strategic value, and no visible 2025 revenue base to defend after the withdrawal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eALBRIOZA was the Canadian brand.\u003c\/li\u003e\n\u003cli\u003eWithdrawal ended mature-market cash flow.\u003c\/li\u003e\n\u003cli\u003eDead-end asset, not a growth driver.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStranded launch costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRelyvrio was shut down after phase 3 failure, so Amylyx Pharmaceuticals, Inc. had sales, manufacturing, and medical support assets sitting idle. In 2023, the company reported $261.0 million in net product revenue from Relyvrio, then took a major write-down and exited the market, leaving stranded launch costs that are hard to recover. Dogs like this usually trap cash and add little to no growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIdle sales force and field support\u003c\/li\u003e\n\u003cli\u003eUnused manufacturing and supply spend\u003c\/li\u003e\n\u003cli\u003eHigh exit losses, low resale value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmylyx’s ALS Asset Turns Into a Dog After Relyvrio’s Collapse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc.'s ALS asset is a Dog: Relyvrio\/ALBRIOZA was withdrawn after PHOENIX missed its endpoint, so the company lost its only product-led growth engine.\u003c\/p\u003e\n\u003cp\u003eNet product revenue was $261.0 million in 2023, then fell to zero after the 2024 exit, leaving stranded sales, manufacturing, and support costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 net product revenue\u003c\/td\u003e\n\u003ctd\u003e$261.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePHOENIX result\u003c\/td\u003e\n\u003ctd\u003ePrimary endpoint missed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-withdrawal revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMX0114 in ALS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMX0114 was Amylyx Pharmaceuticals, Inc.'s next ALS program, aimed at a new neurodegeneration target and still in early clinical testing, so it had 0 market share. In BCG terms, it was a clear Question Mark: high future upside, but no sales yet and no proof of scale. If it worked, it could move toward Star status or stay a small niche asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvexitide in PBH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvexitide is aimed at post-bariatric hypoglycemia, a rare niche tied to the roughly 200,000 U.S. bariatric surgeries done each year; severe PBH is still underserved, with published estimates around 1% to 3% of patients. Amylyx Pharmaceuticals, Inc. had no commercial share at end-2025, so it sits in the Question Mark bucket: high upside, no revenue base. Late-stage data could re-rate the asset fast if efficacy and safety hold.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvexitide in CHI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvexitide in congenital hyperinsulinism targets an ultra-rare pediatric disease, affecting about 1 in 28,000 to 50,000 births, so the addressable market is small but clinically critical. With few approved options and share still being built, Amylyx Pharmaceuticals, Inc. is still investing to prove uptake and fit. That makes Avexitide a classic question mark in the BCG matrix: high need, low current share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMX0035 in Wolfram syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMX0035 in Wolfram syndrome is still a development bet, not a revenue driver. Wolfram syndrome is ultra-rare, with an estimated prevalence of about 1 in 500,000 to 1,000,000 people, so the commercial upside is real but the base is tiny. Amylyx had no established 2025\/2026 revenue from this program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare-disease upside\u003c\/li\u003e\n\u003cli\u003eNo sales base yet\u003c\/li\u003e\n\u003cli\u003eEarly-stage pipeline risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMX0035 in PSP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMX0035 was also tested in progressive supranuclear palsy (PSP), a rare tau-driven disease with no approved disease-modifying therapy and median survival often cited at 6-10 years. That made PSP a high-need market, but Amylyx still had to prove clear efficacy and payer uptake before it could matter commercially.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePSP has no approved cure.\u003c\/li\u003e\n\u003cli\u003eClinical proof was still the hurdle.\u003c\/li\u003e\n\u003cli\u003eAdoption depended on outcomes and access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmylyx’s Question Mark Pipeline: High Upside, No 2025 Sales Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmylyx Pharmaceuticals, Inc.’s Question Marks had high upside but no 2025 sales base: AMX0114, Avexitide, and AMX0035 in rare diseases all stayed in early or mid development, with zero market share and no proven scale. That fits BCG Question Mark status because the assets address small but unmet markets, yet still need late-stage data and adoption to turn into revenue. End-2025, the key test was proof, not size.\u003c\/p\u003e\n\u003cp\u003eAMX0114 had no commercial share and remained an ALS bet, while Avexitide targeted post-bariatric hypoglycemia and congenital hyperinsulinism, both niche rare-disease markets with limited competition. AMX0035 in Wolfram syndrome and PSP also stayed pre-revenue, so Amylyx Pharmaceuticals, Inc. was still funding future optionality rather than harvesting cash.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233989304585,"sku":"amlx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/amlx-bcg-matrix.webp?v=1785710640","url":"https:\/\/dcfanalyst.com\/products\/amlx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}